Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Eben Rosenthal
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02736578CT.gov Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab-Irdye800 (this asset) | Eben Rosenthal | P2 | CCC · 51 |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Docetaxel | Bristol-Myers Squibb | P2 | BBB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Olaparib | Lantern Pharma Inc. | P3 | BB |
| Capecitabine | Zhejiang University | P4 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| Irinotecan Sucrosofate | SWOG Cancer Research Network | P3 | BB |
+42 more in the Pancreatic Adenocarcinoma cohort
Other indications for Cetuximab-Irdye800
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Glioma | — | P1 | CC · 43 |
| Rectal Carcinoma | — | P1 | CC · 42 |
| Glioblastoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetuximab-Irdye800 in Pancreatic Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-irdye800-pancreatic-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →